Logos Global Management’s Cidara Therapeutics CDTX Stock Holding History

Logos Global Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-310,000	Closed	-$68.5M	–	69
2025 Q4	$68.5M	Sell	310,000 -65,000	-17%	-$10.5M	4.14%	6
2025 Q3	$35.9M	Buy	375,000 +185,000	+97%	+$11.8M	3.22%	7
2025 Q2	$9.25M	Buy	+190,000	New	+$4.57M	1.02%	32

Logos Global Management's CDTX Position: Q1 2026 in Review

Logos Global Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 310,000 shares — an estimated $68.5M sold.

Logos Global Management first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $68.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Logos Global Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Logos Global Management sold 310,000 Cidara Therapeutics shares in Q1 2026, an estimated $68.5M.
Logos Global Management first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Logos Global Management's Cidara Therapeutics position peaked at $68.5M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.